FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer

Clinical trial NCT07446465 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07446465
Sponsor: Ye Xu
Status: NOT_YET_RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Colorectal Cancer (Locally Advanced or Metastatic)Colorectal Cancer Microsatellite Stable (MSS)

Start date: 2026-03-01
Primary completion: 2027-01-31
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.